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Plasma Cell Disorders
Introduction
Proteasome inhibition with bortezomib is a cornerstone in
the treatment of multiple myeloma (MM). Initially approved
as a single agent for the treatment of relapsed disease, borte-
zomib is used in frontline therapy for transplant-eligible and -
ineligible patients. Bortezomib prolonged progression-free
and overall survival as induction therapy in candidates for
autologous stem cell transplantation.1,2 In patients with
relapsed MM, Moreau et al. demonstrated with the random-
ized, prospective MMY-3012 study that subcutaneous (SC)
administration of bortezomib reduced toxicity without loss
of efficacy compared to the conventional intravenous (IV)
bolus injections.3,4 Limited data are available on toxicity and
efficacy of SC bortezomib as a combination partner in newly
diagnosed, transplant-eligible patients.5,6
The primary end-points of the randomized, prospective
MM5 phase III trial of the German-Speaking Myeloma
Multicenter Group (GMMG) were responses to VCD (borte-
zomib, cyclophosphamide, dexamethasone) compared to PAd
(bortezomib, doxorubicin, dexamethasone) induction therapy
with respect to high-quality remissions [very good partial
response or better (≥VGPR)] and progression-free survival.7
Based on the data published by Moreau et al., the route of
administration for bortezomib was changed from IV to SC in
both trial arms after 314 of the planned 504 patients had been
enrolled in the MM5 trial. By a protocol amendment the recruit-
ment of 100 additional patients was decided to get comparable
group sizes for IV and SC bortezomib administration. We were,
therefore, able to perform the largest explorative analysis com-
paring toxicity and efficacy of IV and SC bortezomib in two dif-
ferent induction therapies for newly diagnosed MM.
Methods
Patients
Patients with newly diagnosed symptomatic MM according to
CRAB criteria8 were enrolled in the prospective, randomized, open-
label GMMG MM5 phase III trial (EudraCT n. 2010-019173-16) in 31
transplantation centers and 75 associated trial sites throughout
Germany. Patients with systemic AL-amyloidosis or peripheral neu-
ropathy ≥ grade 2 (National Cancer Institute Common Terminology
Criteria for Adverse Events, NCI CTCAE, version 4.0) were excluded
(more detailed criteria are available at clinicaltrialsregister.eu). The
ongoing study is being performed in accordance with the Declaration
of Helsinki and the European Clinical Trial Directive (2005) and was
approved by the local ethics committees of all participating institu-
tions.
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We investigated the impact of subcutaneous versus intravenous bortezomib in the MM5 trial of the German-
Speaking Myeloma Multicenter Group which compared bortezomib, doxorubicin, and dexamethasone with
bortezomib, cyclophosphamide, and dexamethasone induction therapy in newly diagnosed multiple myeloma.
Based on data from relapsed myeloma, the route of administration for bortezomib was changed from intravenous
to subcutaneous after 314 of 604 patients had been enrolled. We analyzed 598 patients who received at least one
dose of trial medication. Adverse events were reported more frequently in patients treated with intravenous borte-
zomib (intravenous=65%; subcutaneous=56%, P=0.02). Rates of grade 2 or more peripheral neuropathy were
higher in patients treated with intravenous bortezomib during the third cycle (intravenous=8%; subcuta-
neous=2%, P=0.001). Overall response rates were similar in patients treated intravenously or subcutaneously. The
presence of International Staging System stage III disease, renal impairment or adverse cytogenetic abnormalities
did not have a negative impact on overall response rates in either group. To our knowledge this is the largest study
to present data comparing subcutaneous with intravenous bortezomib in newly diagnosed myeloma. We show
better tolerance and similar overall response rates for subcutaneous compared to intravenous bortezomib. The
clinical trial is registered at eudract.ema.europa.eu as n. 2010-019173-16.
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ABSTRACT
Study design
The trial was designed to assess two primary objectives: (i) the
non-inferiority of VCD to PAd induction therapy with respect to
rates of VGPR or better; (ii) the best treatment strategy with
regards to progression-free survival. Treatment was PAd or VCD
induction therapy, high-dose melphalan followed by autologous
stem cell transplantation as well as consolidation and maintenance
therapies with lenalidomide for 2 years or until complete response
(Figure 1). Recruitment of the final 604 patients was completed in
November 2013.
Induction therapy
Patients’ randomization was stratified by International Staging
System (ISS) stage.9 The patients were equally distributed in four
treatment arms to receive three cycles of PAd (bortezomib 1.3
mg/m2, days 1, 4, 8 and 11; doxorubicin 9 mg/m2 IV, days 1-4; dex-
amethasone 20 mg/day, orally, days 1-4, 9-12 and 17-20, repeated
every 28 days) or three cycles of VCD (bortezomib 1.3 mg/m2,
days 1, 4, 8 and 11; cyclophosphamide 900 mg/m2 IV; day 1, dex-
amethasone 40 mg/day, orally, days 1-2, 4-5, 8-9 and 11-12,
repeated every 21 days). After 314 patients had been enrolled, the
route of administration of bortezomib was changed from IV to SC
in February 2012.
Assessments
Adverse events were graded using the NCI CTCAE catalogue,
version 4.0. All CTCAE grade ≥3 adverse events were recorded as
were grade ≥2 infections, cardiac disorders, peripheral neuropathy
and thromboembolic events. Response after three cycles was eval-
uated according to International Myeloma Working Group recom-
mendations, which were modified to include near complete
remission.10 Interphase fluorescence in situ hybridization analysis
was accomplished on CD138-purified plasma cells to identify
cytogenetic abnormalities. As described previously, deletion 17p,
t(4;14) and gain 1q21 >2 copies were defined as adverse cytogenet-
ic abnormalities.11
Statistical analysis
Comparison of IV versus SC bortezomib in the PAd and VCD
regimens was performed after 604 patients had finished induction
therapy as of July 2014. An explorative analysis was based on the
safety population, which comprises all patients who received at
least one dose of trial medication. Adverse events associated with
induction are defined as adverse events during induction cycles
and within 30 days after the end of the last induction cycle and
prior to the start of mobilization. Adverse events are summarized
on a per patient basis with the highest CTC grade per site and
patient reported. A Fisher exact test was used to compare frequen-
cies of adverse events and response rates. All P-values were two-
sided. P-values below 0.05 were considered statistically signifi-




Out of 604 randomized patients, six patients did not
receive the allocated trial medication and were excluded
from the safety population. In total, 296 patients were treat-
ed with PAd and 302 patients with VCD. In both arms 51%
of patients were treated with IV bortezomib (PAd n=150;
VCD n=154) and 46-47% with SC bortezomib (PAd n=140;
VCD n=140). Since route of administration was changed
during ongoing induction therapy, 14 patients were exclud-
ed from the current analysis. The CONSORT diagram for
the study is depicted in Figure 2. The patients’ baseline char-
acteristics are summarized in Table 1.
Trial medication
In the PAd group 92% of IV-treated and 97% of SC-
treated patients completed the scheduled three cycles. In
the VCD arm, 98% of both IV- and SC-treated patients
completed three cycles. Proportions of patients receiving
scheduled or delayed full dose trial medication and dose
modifications for bortezomib are reported in Online
Supplementary Table S1. Cumulative bortezomib doses
were significantly higher for SC-treated patients in both
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Table 1. Baseline patients’ and disease characteristics.                                                                                                                                              
                                                               PAD n. (%)                                                          VCD n. (%) 
                                                     IV 150 (52)                            SC 140 (48)                          IV 154 (52)                                 SC 140 (48) 
Age                                                                                                                                                                                                                                                   
median (range)                                            59 (32 - 70)                                                                          58 (33 - 70)
> 65 years                                               39 (26)                                           40 (29)                                         25 (16)                                                  35 (25) 
Sex (female)                                            68 (45)                                           59 (42)                                         64 (42)                                                  55 (39) 
Body mass index (> 30 kg/m2)             24 (16)                                           29 (21)                                         31 (20)                                                  22 (16) 
Immunoglobulin                                                                                                                                                                                                                            
IgG                                                             88 (59)                                            85 (61)                                          88 (57)                                                  97 (69)
IgA                                                             32 (21)                                            30 (21)                                          34 (22)                                                  22 (16) 
Bence Jones                                           28 (19)                                            23 (16)                                          29 (19)                                                  18 (13)
Other                                                          2 (1)                                                2 (1)                                              3 (2)                                                      3 (2)
Creatinine (> 2 mg/dL)                         25 (17)                                           16 (11)                                         19 (12)                                                  19 (14) 
LDH (>ULN)                                            25 (17)                                           26 (19)                                         25 (16)                                                  25 (18) 
ISS stage III                                              41 (27)                                           37 (26)                                         42 (27)                                                  37 (26) 
t(4;14)                                                        19 (13)                                            11 (8)                                          17 (11)                                                    7 (5) 
Del17                                                          20 (13)                                           14 (10)                                         15 (10)                                                   13 (9)
+1q21 > 2 copies                                    61 (41)                                           56 (40)                                         61 (40)                                                   60 (43 
PAD: bortezomib / doxorubicin / dexamethasone; VCD: bortezomib / cyclophosphamide / dexamethasone; IV: intravenous; SC: subcutaneous; LDH: lactate dehydrogenase; ULN:
upper limit of normal; ISS: International Staging System; t: translocation; del: deletion.
arms (median doses PAd: IV 27.6 mg / SC 28.9 mg; VCD:
IV 27.9 mg / SC 28.8 mg; P=0.04).
Safety and toxicity
Safety profiles of SC and IV bortezomib are shown in
Table 2. Grade ≥2 and ≥3 adverse events were reported
more frequently in patients treated with IV bortezomib
than in those treated with SC bortezomib (grade ≥2: 65%
versus 56%; grade ≥3: 55% versus 44%, respectively). In
detail, IV-treated patients more often developed grade ≥2
peripheral neuropathy during the last cycle of induction
therapy (8% versus 2%, P=0.001). There were no signifi-
cant differences in reversibility of peripheral neuropathy
between SC- and IV-treated patients, since 36% of
patients in both groups showed no improvement of
peripheral neuropathy (Table 2). Furthermore, IV-treated
patients had significantly higher rates of gastrointestinal
events (10% versus 4%; P=0.006) as well as metabolic and
nutritional disorders (13% versus 5%; P=0.004). No signif-
icant differences were found for serious adverse events or
deaths related to induction therapy (Table 2).
Response
There were no significant differences in overall response
rates (defined as partial response or better) between IV-
and SC-treated patients in the PAd (IV=73%; SC=71%)
and VCD (IV=78%; SC=82%) groups (Table 3).
Analysis of high quality responses revealed that IV-treat-
ed patients in the VCD arm achieved higher rates of
≥VGPR than SC-treated patients (42% versus 29%,
P=0.02). Differences in rates of ≥VGPR did not reach sta-
tistical significance in the PAd arm (IV: 37% versus SC:
31%, P=0.39). The difference was particularly pronounced
in patients with adverse cytogenetic abnormalities (IV:
45% versus SC: 29%, P=0.05) (Table 3).
Subgroup analysis of patients with cytogenetic abnor-
malities, baseline creatinine values > 2mg/dL or ISS stage
III did not reveal significant differences in overall response
rates between patients treated with IV or SC bortezomib
in the two arms (Table 3).
Discussion
The present explorative analysis of the GMMG MM5
study is, to our knowledge, the largest comparison of IV
and SC bortezomib from a prospective trial in newly diag-
nosed MM. We confirm data presented by Moreau et al.
for relapsed disease.3 We also observed reduced toxicity
and non-inferiority in terms of overall response rate. The
presence of ISS stage III disease, renal impairment or cyto-
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Table 2. Summary of adverse events, serious adverse events and
deaths.
Adverse event IV n (%) SC n (%) P
Any ≥ grade 2 198 (65) 156 (56) 0.02
Infections and infestations 77 (25) 54 (19) 0.09
Cycle 1 41 (14) 28 (10) n.s.
Cycle 2 27 (9) 22 (8)
Cycle 3 13 (5) 13 (5)
Blood and lymphatic system disorders 49 (16) 30 (11) 0.06
Cycle 1 36 (12) 20 (7) n.s.
Cycle 2 17 (6) 13 (5)
Cycle 3 11 (4) 10 (4)
Hematotoxicity
Anemia 22 (7) 12 (4) n.s.
Leukopenia 72 (24) 57 (20)
Thrombocytopenia 17 (6) 13 (5)
Metabolic and nutritional disorders 38 (13) 15 (5) <0.01
Cycle 1 24 (8) 11 (4) n.s.
Cycle 2 11 (4) 4 (1)
Cycle 3 10 (4) 5 (2)
Gastrointestinal disorders 30 (10) 11 (4) <0.01
Cycle 1 18 (6) 4 (1) <0.01
Cycle 2 11 (4) 4 (1) n.s.
Cycle 3 5 (2) 3 (1)
Peripheral neuropathy 35 (12) 23 (8) 0.21
Cycle 1 5 (2) 7 (3) n.s.
Cycle 2 7 (2) 10 (4)
Cycle 3 23 (8) 5 (2) <0.01
Grading of neuropathy
grade 2 26 (9) 19 (7) n.s.
grade 3 9 (3) 4 (1)
grade 4 0 (0) 0 (0)
Outcome of neuropathy per patient*
not resolved 15 (36) 9 (36) n.s.
improved 22 (52) 10 (40)
other 5 (12) 6 (24)
duration in days (median + range) 26 (7-243) 66 (20-229)
Serious adverse event IV n (%) SC n (%) P
Any 88 (29) 77 (28) 0.71
Infections and infestations 33 (11) 34 (12) n.s.
Gastrointestinal disorders 18 (6) 8 (3)
Musculoskeletal / connective tissue 9 (3) 7 (3)
Renal and urinary disorders 8 (3) 5 (2)
Cardiac disorders 5 (2) 6 (2)
Deaths during induction therapy 4 (1) 3 (1)
Any adverse event affecting at least 10% of patients is shown, as is hematotoxicity.
Adverse events CTCAE grade ≥3 were recorded as were grade ≥2 infections and periph-
eral neuropathy. With regards to serious adverse events, the five most reported are
shown. IV: intravenous; SC, subcutaneous; n.s., not significant. *Evaluation of outcome
was not summarized on a per patient basis in contrast to general adverse event assess-
ment, i.e. patients who developed new symptoms after resolved neuropathy were
recorded again. Statistically significant differences are shown in bold.
Figure 1. Flow chart of the GMMG MM5 study. Patients were random-
ized to four treatment arms with either PAd (2 arms) or VCD (2 arms)
induction therapy and lenalidomide maintenance therapy either for 2
years or until complete remission was achieved. ASCT: autologous
stem cell transplantation; CR: complete response; nCR: near com-
plete remission.
genetic abnormalities at initial presentation did not have a
negative impact on overall response rate in either SC- or
IV-treated patients.
Early phase I trials of bortezomib in relapsed MM iden-
tified gastrointestinal as well as metabolic disorders (e.g.
hypokalemia, hyponatremia) and peripheral neuropathy
as dose-limiting toxicities.12,13 In our current study we
demonstrate that these adverse events can be reduced by
SC administration of bortezomib, which is in line with
data from Moreau et al.3 (MMY-3021 trial). Although this
trial is especially known for demonstrating a reduction of
peripheral neuropathy with the use of SC bortezomib, the
study also showed a reduction of gastrointestinal adverse
events in accordance with our data.
Differences in peripheral neuropathy between SC- and
IV-treated patients became evident in the last (third) cycle
of induction therapy. An explanation for this finding is the
cumulative dose-dependent occurrence of peripheral neu-
ropathy in IV-treated patients.14 In MMY-3021 the cumula-
tive bortezomib dose was also linked to the incidence of
peripheral neuropathy in SC-treated patients. However,
for the same dose, peripheral neuropathy was less fre-
quent with SC bortezomib than with IV bortezomib.3
Because peripheral neuropathy leads to dose reductions, in
our study and in MMY-3021 cumulative doses were high-
er in SC-treated patients than in IV-treated ones.3 An
explanation for reduced rates of peripheral neuropathy
despite higher cumulative doses after SC administration is
that maximum bortezomib plasma concentrations are
lower than after IV bolus injections.15,16 Since recent studies
identified tumor and host factors associated with suscep-
tibility for bortezomib-induced neuropathy,17,18 the deci-
sive factor remains uncertain. These studies underline that
drug exposure alone does not determine the occurrence of
bortezomib-induced peripheral neuropathy.
Thrombocytopenia is the most frequent dose-limiting
hematologic toxicity of bortezomib.13 Contrary to the
MMY-3021 study that showed reduced thrombocytope-
nia in SC-treated patients,3 no difference in grade ≥3
thrombocytopenia or any other hematologic toxicity was
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Figure 2. CONSORT diagram
of the GMMG MM5 trial.
Overall 604 patients were ran-
domly assigned to four treat-
ment arms with either PAd (2
arms) or VCD (2 arms) induc-
tion therapy. Analysis compar-
ing IV with SC bortezomib in
both arms was performed on
the safety population which
comprises all patients receiv-
ing at least one dose of allo-
cated trial medication. Six
PAd-treated and eight VCD-
treated patients were exclud-
ed from the analysis since the
treatment protocol was violat-
ed and route of administration
was changed during ongoing
induction therapy.
Table 3. Summary of treatment response after induction therapy.
PAd n. (%) VCD n. (%)
All IV SC P IV SC P
≥ PR 109 (73) 99 (71) 0.79 120 (78) 115 (82) 0.39
≥ VGPR 55 (37) 44 (31) 0.39 64 (42) 40 (29) 0.02
nCR/CR 34 (23) 25 (18) 0.38 41 (27) 20 (14) 0.01
Baseline creatinine ≥ 2 mg/dL
≥ PR 15 (60) 9 (56) 1.00 15 (79) 16 (84) 1.00
≥ VGPR 10 (40) 7 (44) 1.00 12 (63) 9 (47) 0.51
nCR/CR 4 (16) 3 (19) 1.00 9 (47) 2 (11) 0.03
ISS stage III
≥ PR 25 (61) 23 (62) 1.00 28 (67) 30 (81) 0.20
≥ VGPR 15 (37) 13 (35) 1.00 17 (41) 15 (41) 1.00
nCR/CR 8 (20) 7 (19) 1.00 9 (21) 7 (19) 1.00
Adverse cytogenetic abnormalities
≥ PR 52 (71) 42 (67) 0.58 54 (82) 56 (86) 0.63
≥ VGPR 33 (45) 18 (29) 0.05 29 (44) 19 (29) 0.10
nCR/CR 20 (27) 12 (19) 0.31 15 (23) 12 (19) 0.67
Overall response rates (partial response or better) as well as rates of ≥VGPR and (near) complete remission are shown for the whole study population. Subgroup analysis was
performed for patients with renal impairment (baseline creatinine values ≥ 2 mg/dL), high tumor burden (ISS III) and adverse cytogenetic abnormalities. PAd: bortezomib / dox-
orubicin / dexamethasone; VCD: bortezomib / cyclophosphamide / dexamethasone; IV: intravenous; SC: subcutaneous; ≥PR: partial response or better; ≥VGPR: very good partial
response or better; nCR: near complete remission; CR: complete remission; ISS: International Staging System.
Patients not receiving
allocated intervention:
- no confirmed diagnosis of
multiple myeloma (n=1)
- myocardial infarction (n=1)
-death (n=1)
-randomized to PAd
treated with VCD (n=1)
Patients not receiving
allocated intervention:
- consent withdrawn (n=2)
- non-compliance (n=1)
6 excluded due to
mixed application
8 excluded due to
mixed application
observed in the current study. The comparison is ham-
pered since patients in MM5 had no prior exposure to
cytotoxic agents.
Our current study confirmed that overall response rates
are not lower in patients treated with SC bortezomib than
in those treated with IV bortezomib. The highest overall
response rate among all analyzed subgroups was seen in
patients treated with SC bortezomib and VCD.
Furthermore, we showed for the first time that overall
response rates in SC-treated patients are not influenced by
the presence of adverse cytogenetic abnormalities, ISS stage
III or renal impairment. In contrast to the results of MMY-
3021 we observed lower rates of ≥VGPR in patients treated
with SC bortezomib and VCD. This is also in contrast to
findings of recent observational studies that incorporated
SC bortezomib into VTD (bortezomib, thalidomide, dex-
amethasone) or VCD induction therapy.5,6 In both non-com-
parative studies, which included small numbers of patients
(n=31 and n=22),5,6 rates of ≥VGPR exceeded 50% and were
comparable to those of previously published trials of the
VTD regimen with IV bortezomib.19-21 In both studies and
MMY-3021 response was assessed after four cycles, while
in MM5 only three cycles of induction therapy were admin-
istered. Several phase II and phase III trials of bortezomib-
based induction therapies reported higher rates of ≥VGPR
after four to six cycles.22 The reduced toxicity of SC borte-
zomib demonstrated in the current study enables prolonged
pre-transplant treatment to achieve higher rates of ≥VGPR,
which is an important predictor of survival after autologous
stem cell transplantation.23
The issue concerning combination partners in borte-
zomib-based induction therapies also remains controver-
sial.1,22 The MM5 trial was the first phase III trial to show
non-inferiority of two different bortezomib-based induc-
tion therapies with respect to rates of ≥VGPR.7
Additionally, VCD was shown to have a better toxicity
profile than PAd.7 We, therefore, recommend VCD as
induction therapy before autologous stem cell transplanta-
tion. Immunomodulatory drugs, such as thalidomide and
lenalidomide,24 are frequently used as combination part-
ners in bortezomib-based induction therapies. Data on SC
bortezomib incorporated into both regimens are limited
and so far no phase III trial has addressed the comparison
of conventional chemotherapy or an immunomodulatory
drug as a combination partner for bortezomib. Data from
the IFM 2013-04 trial (NCT trial n. 01971658) in newly
diagnosed MM comparing VTD with VCD induction ther-
apy will shed new light on this important issue. In both
trial arms patients will receive SC bortezomib.
There are limitations to the present analysis, since the
MM5 trial was not designed to prospectively evaluate tox-
icity and efficacy of IV and SC bortezomib in PAd or VCD.
Furthermore, longer follow-up is needed to evaluate
whether lower rates of ≥VGPR in SC-treated patients will
lead to differences in progression-free and overall survival
after autologous stem cell transplantation and lenalido-
mide consolidation / maintenance therapy.
In conclusion, compared to IV bortezomib, SC borte-
zomib in PAd and VCD induction therapy reduced toxici-
ty and achieved similar overall response rates, regardless
of whether adverse prognostic factors such as ISS stage III
disease, renal impairment or cytogenetic abnormalities
were present at initial diagnosis.
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